Bavarian begins phase II trial with RSV vaccine
Danish biotech Bavarian Nordic is initiating a phase II trial in the US with its experimental RSV vaccine. The CEO calls it an “important milestone” for the company.
BY ELIZABETH MØNSTED JOHANSEN
Bavarian Nordic has announced the initiation of a phase II study with its experimental vaccine MVA-BN RSV against respiratory syncytial virus (RSV). The study follows what the company called “extremely promising results” from a phase I trial announced earlier this year.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bavarian Nordic aims to raise USD 100 million
For abonnenter
Bavarian initiates new Prostvac study
For abonnenter
